Vivos Therapeutics (VVOS)
Oral-appliance therapy, sleep testing and clinical-practice support for obstructive sleep apnea.
Something off on this page? Send us feedback.
Sells oral appliances and delivers sleep-testing and treatment services for obstructive sleep apnea, combining devices with clinical support, billing and practice-management services. The model is shifting from training independent dental providers to owned or managed practices supported through management-service structures.
Combines C.A.R.E. oral appliances—custom DNA, mRNA and mmRNA devices—with VivoScore home sleep testing, clinical protocols and adjunctive therapies for breathing-related sleep disorders, principally obstructive sleep apnea. MyoSync provides orofacial myofunctional therapy, while billing and practice-management tools support treatment delivery.
Expanding from training independent dental providers into operating and managing medical sleep practices. Sleep and Airway Medicine Centers use medical, dental, clinical-assistant, administrative and patient-navigation roles; owned or managed operations are concentrated in Nevada and Michigan, and the United States is the principal market.
Earns service revenue from sleep testing, treatment centers, billing, therapy and legacy provider programs, alongside appliance and tooth-positioner sales. The MSO/DSO model requires clinical functions to remain with licensed professional entities and depends on compliance with state practice, fee-splitting, anti-kickback and independent-judgment rules.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Apr 17, 2026 | H.C. Wainwright | Target | Target: — | Target: $2.50 |
| Apr 17, 2026 | Industrial Alliance Securities | Target | Target: $2.25 | Target: $1.75 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $12.1M · Total assets $24.1M · Shareholders' equity −$3.8M
- Revenue
- $5.2M
- Operating income
- −$4.8M
- Net income
- −$5.5M
No dividends on record.
| Institutions | 3.82% | 531.0K shares | |
|---|---|---|---|
| 22 holders · as of Jun 30, 2026 | |||
| Insiders | 3.40% | 472.6K shares | |
| 4 holders · as of Aug 26, 2026 | |||
| Strategic holders | 30.81% | 4.28M shares | |
| 3 holders · as of Aug 11, 2026 | |||
| Other | 61.97% | 8.61M shares | |
| remainder | |||
13.89M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (20.12M in the company's Sep 23, 2026 report, 13.89M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Streeterville Capital LLCStrategic | 13.04% | 1.81M | filed Aug 11, 2026 |
V-Co Investors 3 LLCStrategic10 percent owner | 9.74% | 1.35M | filed Apr 10, 2026 |
Armistice Capital, LLCStrategic | 8.03% | 1.12M | filed May 15, 2026 |
Bradford K. AmmanInsiderofficer: Principal Accounting Officer | 1.80% | 250,080 | filed Aug 26, 2026 |
Dave SinghInsider | 0.94% | 129,988 | filed Feb 14, 2022 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 30, 2026 | Michael C. Skaff | 10 percent owner | +5,498,660 | $0.4560 |
| Mar 31, 2026 | Michael C. Skaff | 10 percent owner | +5,350,746 | $1.07 |
- ResMed
PAP devices and connected diagnostics contend for OSA patients.
- Inspire Medical Systems
Implantable neurostimulation alternative for moderate-to-severe OSA.
- Nyxoah
Bilateral HGNS option for PAP-intolerant moderate-to-severe OSA.
- Eli Lilly
Drug alternative for obese adults with moderate-to-severe OSA.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vivos Therapeutics | $0.1470 | −6.13% | $2.2M | — | — | 0.1 | +34.9% |
| ResMed | $222.49 | +0.23% | $32.20B | 21.3 | 18.3 | 5.7 | +8.6% |
| Inspire Medical Systems | $69.59 | −2.40% | $2.06B | 15.4 | 54.0 | 2.3 | −7.6% |
| Nyxoah | $1.34 | −4.29% | $140.1M | — | — | 5.4 | +455.6% |
| Eli Lilly | $1,158.45 | −1.00% | $1.10T | 39.3 | 28.3 | 13.8 | +47.7% |
| Median | 21.3 | 28.3 | 5.6 | +28.1% |